Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Recruiting 2Completed 2Terminated 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5Thoracic 1NET 1Head & Neck 1Endocrine 1CNS 1Breast 1

Conditions

Leukemia, Myeloid, Acute 229Leukemia, Lymphocytic, Chronic, B-Cell 213Leukemia 203Myelodysplastic Syndromes 185Precursor Cell Lymphoblastic Leukemia-Lymphoma 174Lymphoma 148Lymphoma, Non-Hodgkin 142Multiple Myeloma 131Hodgkin Disease 123Lymphoma, Follicular 111Lymphoma, Mantle-Cell 108Lymphoma, Large B-Cell, Diffuse 96Lymphoma, B-Cell, Marginal Zone 89Myeloproliferative Disorders 86Congenital Abnormalities 85Burkitt Lymphoma 85Leukemia, Myelomonocytic, Chronic 77Leukemia, Myelogenous, Chronic, BCR-ABL Positive 75Leukemia, Myeloid, Chronic-Phase 74Leukemia, Myeloid, Accelerated Phase 73Recurrence 63Melanoma 62Lymphoma, Large-Cell, Immunoblastic 61Anemia, Refractory, with Excess of Blasts 60Neoplasms, Plasma Cell 56Waldenstrom Macroglobulinemia 55Primary Myelofibrosis 55Blast Crisis 55Hematologic Neoplasms 45Lymphoma, T-Cell, Cutaneous 42

Interventions

Ipilimumab 29Nivolumab 23pembrolizumab 14incomplete Freund's adjuvant 10Cyclophosphamide 10Melphalan 9Interleukin-2 9CTLA-4 Antigen 8tebentafusp 7sargramostim 7Temozolomide 7MART-1 Antigen 7Dacarbazine 7Ranibizumab 6montanide ISA 51 5fludarabine phosphate 5fludarabine 5Sunitinib 5Radiosurgery 5Carboplatin 5Blood Specimen Collection 5Bevacizumab 5aldesleukin 4aflibercept 4Surveys and Questionnaires 4Magnetic Resonance Spectroscopy 4Granulocyte-Macrophage Colony-Stimulating Factor 4Biopsy 4trametinib 3sotrastaurin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Uveal Melanoma × fludarabine phosphate × Clear all
NCT07627698 2026-06-04

DUET-MEL

Beijing Biotech

Phase 1/2 Recruiting
36 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT05628883 2026-04-02

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
17 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Stanford University

Phase 1 Recruiting
18 enrolled
BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT01814046 2018-10-11

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
24 enrolled 13 charts
Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT00313508 2014-02-21

Dendritic Cell Vaccination During Lymphoid Reconstruction

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
18 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡